Diabetes - Adult stem cells as an future alternative therapy?

Bratislava Medical Journal

Volumn 110, Issue 12, 2009, Pages 773-776

  Ulicna, M ^a   Danisovic, L ^a   Danihel, L ^a   Vojtassak, J ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

Adult stem cells; Diabetes; Therapy

Indexed keywords

ADULT STEM CELL; ANIMAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; REVIEW; TRANSPLANTATION;

ADULT STEM CELLS; ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; REGENERATION;

EID: 77952992908     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Zlatoš L, Klimeš I. Endokrinná čast' pankreasu. 1101-1134. In: Hulin I et al. Patofyziologia. Bratislava; SAP, 2002.
2. Noguchi H. Stem cells for the treatment of diabetes. Endocrine J 2007; 54 (1): 7-16.
3. Liu M, Han ZC. Mesenchymal stem cells: Biology and clinical potential in Type 1 diabetes therapy. J Cell Mol Med 2008; 12(4): 1155-1168.
4. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: Resolved and unresolved issues. J Clin Invest 2001; 108: 1247-1252.
5. Stuchlikova M, Kantarova D, Michalkova D, Barak L, Buc M. Association of HLA-DPB1 alleles with type I diabetes mellitus in Slovak population. Bratisl Lek Listy 2006; 107 (3): 73-75.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986.
7. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type-1 diabetes. Lan cet 1993; 341: 1306-1309.
8. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Amer Med Ass 2003; 290: 2159-2167.
9. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836.
10. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swier-giel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
11. Kues WA, Petersen B, Mysegades W, Carnwath JW, Niemann H. Isolation of murine and porcine fetal stem cells from somatic tissue. Biol Reprod 2005; 72: 1020-1028.
12. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004; 8: 301-316.
13. Barry FP, Murphy JM. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36 (4): 568-584.
14. Henon PR. Human embryonic or adult stem cells: An overview on ethics and perspectives for tissue engineering. Adv Exp Med Biol 2003; 534: 27-45.
15. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004; 32: 414.
16. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890.
17. Zulewski H, Abraham EJ, Gerlach MJ, Daniel PB, Moritz W, Miiller B, Vallejo M, Thomas MK, Habener JF. Multipotentialne-stin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 2001; 50: 521-533.
18. Gu G, Brown JR, Melton DA. Direct lineage tracing reveals the ontogeny of pancreatic cell fates during mouse embryogenesis. Mech Dev 2003; 120 (1): 35-43.
19. Bernard-Kargar C, Ktorza A. Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 2001; 50 Suppi 1: 30-35.
20. Bonner-Weir S, Sharma A. Are there pancreatic progenitor cells from which new islets form after birth? Nat Clin Pract Endocrinol Me-tab 2006; 2: 240-241.
21. Bonner-Weir S, Taneja M, Weir GC, Tatarkiewicz K, Song KH, Sharma A, O'Neil JJ. In vitro cultivation of human islets from expandedductal tissue. Proc Natl Acad Sci USA 2000; 97: 7999-8004.
22. Ramiya V, Schatz D. Islet replacement vs. Regeneration: Hope or hype? Pediatr Diabet 2004; 5 Suppl 2:45-56.
23. Xia B, Zhan XR, Yi R, Yang B. Can pancreatic duct-derived progenitors be a source of islet regeneration? Biochem Biophys Res Commun. 2009 Mar 24. [Epub ahead of print]
24. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 1998; 128: 517-523.
25. Elliott RB, Crossley JR, Berryman CC, James AG. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet 1981; 19: 631-632.
26. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine. Diabetes 1985; 34:1306-1308.
27. Cook JJ, Hudson I, Harrison LC et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type 1 diabetes. Diabetes 1989; 38: 779-783.
28. Silverstein J, Maclaren N, Riley W et al. Immunosupression with azatioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. New Engl J Med 1988; 319: 599-604.
29. Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Dia betes 1988; 37: 1574-1582.
30. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. New Engl J Med 2002; 346: 1692-1698.
31. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New Engl J Med 2005; 352: 2598-2608.
32. Raz I, Elias D, Avron A, Metzger M, Cohen IR. Beta-cell function in newly-onset type 1 diabetes and immunomodulation with a heat shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001; 358: 1749-1753.
33. Saudek F, Havrdova T, Boucek P, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004; 1: 80-88.
34. Sutherland DE, Gores PF, Farney AC, Wahoff DC, Matas AJ, Dunn DL, Gruessner RW, Najarian JS. Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. Amer J Surg 1993; 166: 456-491.
35. Bretzel RG, Browatzki CC, Schultz A, Brandhorst H, Klitscher D, Bollen CC, Raptis G, Friemann S, Ernst W, Rau WS, Hering BJ. Clinical islet transplantation in diabetes mellitus-report of the Islet Transplant Registry and the Giessen Center experience. Diab Stoffw 1993; 2: 378-390.
36. Jun HS, Yoon JW. Approaches for the cure of type 1 diabetes by cellular and gene therapy. Curr Gene Ther 2005; 5 (2): 249-262.
37. Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-de-pendent neoangiogenic response in vivo. Gene Ther 2003; 10: 621-629.
38. Gruber R, Kandler B, Holzmann P, Vögele-Kadletz M, Losert U, Fischer MB, Watzek G. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Engl 2005; 11: 896-903.
39. Oswald J, Boxberger S, Jřrgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004; 22: 377-384.
40. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulat Res 2004; 94: 678-685.
41. Theise ND, Nimmakayalu M, Grender R et al. Liver from bone marrow in humans. Hepatology 200; 32: 11-16.
42. Korbling M, Katz RL, Khanna A et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral blood stem cells. New Engl J Med 2002; 346: 738-746.
43. Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest 2003; 111: 843-850.
44. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, Thyssen S, Gray DA, Bhatia M. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003; 21: 763-770.
45. Urbán VS, Kiss J, Kovács J, Gócza E, Vas V, Monostori E, Uher F. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008; 26: 244-253.
46. Lee SH, Hao E, Savinov AY, Geron I, Strongin AY, Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: Implications for diabetes cell therapies. Transplantation. Transplantation 2009; 87 (7): 983-991.
47. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Sim•es BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. J Amer Med Ass 2007; 297 (14): 1568-1576.